<DOC>
	<DOCNO>NCT00881322</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled trial determine safety efficacy Digestive Advantageâ„¢ Gas Defense formula , probiotic dietary supplement . The study last approximately four week , subject see screening/randomization visit , two follow-up visit . Study procedure include administer questionnaire assessment study product 's effect intestinal gas symptom quality life .</brief_summary>
	<brief_title>A Study Intestinal Gas Symptoms Evaluate Effects Gas Defense Otherwise Healthy Adult</brief_title>
	<detailed_description />
	<mesh_term>Abdominal Pain</mesh_term>
	<mesh_term>Flatulence</mesh_term>
	<mesh_term>Colic</mesh_term>
	<criteria>Subject 1875 year age . Subject selfreports least one follow symptom eat meal snack : Abdominal pain/cramps Distended feeling/bloating Flatulence/gas Subject otherwise general good health determine physical exam medical history . Subject willing able comply protocol . Female subject define postmenopausal ( exclude hysterectomized post bilateral tubal ligation ) must use reliable method birth control define within protocol . Subject able understand sign inform consent ( English Spanish ) participate study . Subject follow medical condition : active heart disease renal hepatic impairment/disease Type I II diabetes psychiatric disorder ( hospitalize within past one year ) bipolar disorder Parkinson 's disease unstable thyroid disease immune disorder ( HIV/AIDS ) medical condition deem exclusionary Principal Investigator ( PI ) Subject history cancer ( except localize skin cancer without metastasis situ cervical cancer ) within five year prior screen . Subject stomach intestinal surgery ( i.e . gastric bypass ) . Subject currently take antibiotic ( drug significantly interfere bacterial flora ) take antibiotic within 30 day prior screening/enrollment . Subject currently take use past 30 day probiotic prebiotics . Subject unstable dose medication ( define few 90 day dose ) . Subject currently take medication deem exclusionary PI . Subject history currently gastrointestinal disorder inflammatory bowel condition Crohn 's disease , short bowel , ulcerative colitis . Subjects may diagnosis , see doctor , take prescription medication ( ) Irritable Bowel Syndrome ( IBS ) . Subject constipation define less three spontaneous bowel movement per week . Subject lactose intolerant ( selfprofessed diagnose ) . Subject use follow classification GI medication two time per week : antispasmodic , motility agent , prokinetic agent laxative . Subject plan use another overthecounter gasrelief product daily study period . Overthecounter gas relief product may use rescue medication ( use capture study staff ) . If subject use fiber supplement prior start study , he/she may continue long frequency quantity remain stable throughout study period . Subject allergy wheat fish product ingredient ( see section 2.5.4 ) . Subject two food allergy . Subject history drug alcohol abuse within past 12 month . Subject deem Investigator unsuitable candidate receipt investigational dietary supplement , unable follow throughout entire duration study . Female subject childbearing potential unwilling use acceptable form contraceptive device throughout study period . Subject pregnant , lactating , plan become pregnant study period . Subject participate another clinical trial receive investigational product within 30 day prior screening/enrollment . Subject deem Investigator unsuitable candidate receipt investigational dietary supplement , unable follow throughout entire duration study . Subject unable comprehend Informed Consent research purpose . Subject unable unwilling comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>